CXCL10/IP-10/CRG-2 Antibody [Alexa Fluor® 488]

• Reactivity: Mu
• Applications: WB, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 488

CXCL10/IP-10/CRG-2 Antibody [Alexa Fluor® 488] Summary

• Immunogen: E. coli-derived recombinant mouse CXCL10/IP-10/CRG-2
  Ile22-Pro98
  Accession # P17515
• Specificity: Detects mouse CXCL10/IP-10/CRG-2 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant human CXCL10 is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL10/IP-10/CRG-2 Antibody [Alexa Fluor® 488]

• C7
• chemokine (C-X-C motif) ligand 10
• CRG2
• CRG-2
• CXCL10
• gIP-10
• IFI10
• INP10
• IP-10
• mob-1
• SCYB10

Background

The gene for CRG-2, a mouse homolog of human IP-10, was originally identified as an immediate early gene induced in response to macrophage activation. It has since been shown that CRG-2 mRNA is induced by alpha / beta / gamma -interferons and by lipopolysaccharide in macrophages, astrocytes and microglia. Human IP-10 was also shown to be expressed in activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. Mouse CRG-2 cDNA encodes a 98 amino acid (aa) residue precursor protein with a 21 aa residue signal peptide that is cleaved to form the 77 aa residue secreted mature protein. Mature CRG-2 shares approximately 67% amino acid sequence identity with human IP-10. The amino acid sequence of CRG-2 identified the protein as a member of the chemokine alpha subfamily that lacks the ELR domain. CRG-2 has been shown to be a chemoattractant for activated T-lymphocytes. Recently, human IP-10 has also been reported to be a potent inhibitor of angiogenesis and to display a potent thymus-dependent anti-tumor effect. A chemokine receptor specific for IP-10 and MIG (CXCR3) has been cloned and shown to be highly expressed in IL-2-activated T-lymphocytes.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.